Synapse

← Journal of Immunotherapy and Precision Oncology

Papers in Journal of Immunotherapy and Precision Oncology

Page 2 · newest first

  1. MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade ToxicitiesJournal of Immunotherapy and Precision Oncology · 2024
  2. Images in Immunotherapy and Precision Oncology: Advanced Basal Cell CarcinomaJournal of Immunotherapy and Precision Oncology · 2024
  3. Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab TherapyJournal of Immunotherapy and Precision Oncology · 2024
  4. Abstracts Presented at the 2023 Emirates Oncology ConferenceJournal of Immunotherapy and Precision Oncology · 2024
  5. Factors that Influence the Need to Start Adaptive RadiotherapyJournal of Immunotherapy and Precision Oncology · 2024
  6. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint InhibitorsJournal of Immunotherapy and Precision Oncology · 2024
  7. Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1Journal of Immunotherapy and Precision Oncology · 2024
  8. T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A ReviewJournal of Immunotherapy and Precision Oncology · 2024
  9. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only SequencingJournal of Immunotherapy and Precision Oncology · 2023
  10. B7-H3 Inhibitors in Oncology Clinical Trials: A ReviewJournal of Immunotherapy and Precision Oncology · 2023
  11. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future DirectionsJournal of Immunotherapy and Precision Oncology · 2023
  12. Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced MalignanciesJournal of Immunotherapy and Precision Oncology · 2023
  13. Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical TrialsJournal of Immunotherapy and Precision Oncology · 2023
  14. Therapeutic Role of Synthetic Lethality in ARID1A -Deficient MalignanciesJournal of Immunotherapy and Precision Oncology · 2023
  15. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with NivolumabJournal of Immunotherapy and Precision Oncology · 2023
  16. Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate CancerJournal of Immunotherapy and Precision Oncology · 2023
  17. How to Build a Successful Phase I Clinical Trials Unit: Lessons Based on the MD Anderson Cancer Center ExperienceJournal of Immunotherapy and Precision Oncology · 2023
  18. Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT CarcinomaJournal of Immunotherapy and Precision Oncology · 2023
  19. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from MelanomaJournal of Immunotherapy and Precision Oncology · 2023
  20. A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal CancerJournal of Immunotherapy and Precision Oncology · 2023
  21. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of PharmacovigilanceJournal of Immunotherapy and Precision Oncology · 2023
  22. Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia MutationJournal of Immunotherapy and Precision Oncology · 2023
  23. Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New EraJournal of Immunotherapy and Precision Oncology · 2023
  24. Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A ReviewJournal of Immunotherapy and Precision Oncology · 2023
  25. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the LiteratureJournal of Immunotherapy and Precision Oncology · 2023
  26. Translational Studies Using the MALT1 Inhibitor ( S )-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in CancerJournal of Immunotherapy and Precision Oncology · 2023
  27. COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic ReviewJournal of Immunotherapy and Precision Oncology · 2023
  28. Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint InhibitorsJournal of Immunotherapy and Precision Oncology · 2023
  29. The Contemporary Landscape and Future Directions of Intratumoral ImmunotherapyJournal of Immunotherapy and Precision Oncology · 2023
  30. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJournal of Immunotherapy and Precision Oncology · 2023
  31. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the FutureJournal of Immunotherapy and Precision Oncology · 2022
  32. Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and LiverJournal of Immunotherapy and Precision Oncology · 2022
  33. Recent Therapeutic Advances in Pituitary CarcinomaJournal of Immunotherapy and Precision Oncology · 2022
  34. Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast CancerJournal of Immunotherapy and Precision Oncology · 2022
  35. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint InhibitorsJournal of Immunotherapy and Precision Oncology · 2022
  36. Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor ThrombusJournal of Immunotherapy and Precision Oncology · 2022
  37. Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer CenterJournal of Immunotherapy and Precision Oncology · 2022
  38. The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal CancersJournal of Immunotherapy and Precision Oncology · 2022
  39. Of Mice, Not Men: When the Bench-to-Bedside Bridge Is BrokenJournal of Immunotherapy and Precision Oncology · 2022
  40. Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 ImmunotherapyJournal of Immunotherapy and Precision Oncology · 2022
  41. Targeting KRAS : Crossroads of Signaling and Immune InhibitionJournal of Immunotherapy and Precision Oncology · 2022
  42. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A reviewJournal of Immunotherapy and Precision Oncology · 2022
  43. Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case ReportJournal of Immunotherapy and Precision Oncology · 2022
  44. Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University ExperienceJournal of Immunotherapy and Precision Oncology · 2022
  45. Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical OutcomesJournal of Immunotherapy and Precision Oncology · 2022
  46. Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced ColitisJournal of Immunotherapy and Precision Oncology · 2022
  47. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic CholangiocarcinomaJournal of Immunotherapy and Precision Oncology · 2022
  48. The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative ReviewJournal of Immunotherapy and Precision Oncology · 2021
  49. Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled TrialsJournal of Immunotherapy and Precision Oncology · 2021
  50. Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-AnalysisJournal of Immunotherapy and Precision Oncology · 2021